Title: Alexander Kettner - Innovator in Allergy Vaccine Development
Introduction
Alexander Kettner is an inventor based in Lausanne, Switzerland. He is currently associated with Anergis S.A., a company focused on developing innovative solutions for allergy treatment. Although he has not yet been granted any patents, his work in the field of immunotherapy is noteworthy.
Latest Patent Applications
Kettner's latest patent applications include significant advancements in allergy vaccine efficacy. One application titled "Methods of Improving Efficacy of Allergy Vaccines" provides specific immunotherapy methods for allergies. This method involves administering one or more peptides specific to the allergy being treated, incorporated within a virosome and in the presence of a Toll-like receptor (TLR) agonist. Another application, "Contiguous Overlapping Peptides for Treatment of House Dust Mites Allergy," presents contiguous overlapping peptides (COPs) for treating allergic patients through Specific Immunotherapy (SIT). These peptides are derived from the major allergens of house dust mites, Der p 1 and Der p 2. They are designed to provide all potential T cell epitopes while lacking the three-dimensional structure of the original allergen, thereby reducing their ability to bind IgE. This innovation allows for increased amounts of COPs to be administered per injection, ultimately reducing both the number of injections and the duration of immunotherapy treatment.
Conclusion
Alexander Kettner is making strides in the field of allergy treatment through his innovative patent applications. His work has the potential to significantly improve the efficacy of allergy vaccines, paving the way for more effective immunotherapy solutions.